Modulation of serum adiponectin might be involved in mediating the susceptibility to steatosis, NASH, and hepatocellular carcinoma in carriers of the 148 M PNPLA3 variant without CHC, with potential therapeutic implications, but additional studies are required to confirm this hypothesis. The gene discussed is PNPLA3; the disease is steatosis.